AFFY Key Stats
- Update on Ligand/Glaxo's Promacta - Analyst Blog Zacks 02/05 12:00 ET
- Allergan Beats on Earnings by a Penny - Analyst Blog Zacks 02/05 05:23 ET
- Zacks' Bull Of The Day: Affymax Seeking Alpha 01/10 15:43 ET
- AFFYMAX INC Files SEC form 10-Q, Quarterly Report 11/05 16:29 ET
- New Data Show Omontys At Least 4x Worse Than Reported: Now 22 Suspected Deaths Seeking Alpha 10/14 20:13 ET
- IART Accomplishes Shoulder Implant - Analyst Blog Zacks 09/24 12:50 ET
- Affymax downgraded by WBB Securities 09/18 02:30 ET
- Just Like Omontys.com, Affymax Is Likely To Disappear 09/10 16:37 ET
- Don't Believe In Affymax - The Stock Is Probably Worthless 08/29 12:13 ET
- Affymax: Getting The Facts Straight 08/29 09:05 ET
AFFY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Affymax is down 72.34% over the last year vs S&P 500 Total Return up 24.21%, Actelion up 104.6%, and Cytokinetics up 57.32%.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for AFFY
Pro Strategies Featuring AFFY
Did Affymax make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Affymax, Inc., is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions.